Phaseline

Targets › NLRP3

NLRP3 (NACHT, LRR and PYD domains-containing protein 3): drug programs, companies and trials

3 programs from 3 companies in 6 trials: 3 Phase 1, 3 Phase 2; Neurology, Metabolic and endocrine, Immunology; next expected readout Dec 2026.

Sensor component of the NLRP3 inflammasome, which mediates inflammasome activation in response to defects in membrane integrity, leading to secretion of inflammatory cytokines IL1B and IL18 and pyroptosis. In response to pathogens and other damage-associated signals that affect the integrity of membranes, initiates the formation of the inflammasome polymeric complex composed of NLRP3, CASP1 and PYCARD/ASC.…. (UniProt, Q96P20)

Open in Phaseline: the race on NLRP3, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Olatec TherapeuticsDapansutrile
NACHT, LRR and PYD domains-containing protein 3 inhibitor
NLRP3Phase 2Acute Gout Flare; Parkinson Disease; Diabetes Mellitus, Type 2; MelanomaDec 2026
AC ImmuneACI-19764
NLRP3 inflammasome inhibitor
NLRP3Phase 1Healthy ParticipantsDec 2026
Highlightll Pharmaceutical (USA)HL-400
NLRP3 inflammasome inhibitor
NLRP3Phase 1Parkinson Disease–

Conditions

Parkinson Disease (2) Acute Gout Flare (1) Diabetes Mellitus, Type 2 (1) Melanoma (1) Healthy Participants (1)

Modalities

small molecule (3)

Companies

Highlightll Pharmaceutical (USA) (1) Olatec Therapeutics (1) AC Immune (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.